Issues
-
Cover Image
Cover Image
Specific small-molecule inhibitors of MEK are promising anticancer agents targeting the oncogenic RAF-MEK-ERK pathway. Breast cancer, as in most solid malignancies, is a phenotypically and molecularly heterogeneous disease. It is unclear whether individual breast cancer subtypes are particularly susceptible to these agents. Mirzoeva and colleagues used a systems-based approach to identify such subtypes and to understand molecular mechanisms conferring resistance to MEK inhibitors. Basal-type breast cancer cells were found to be particularly susceptible to growth-inhibition by small-molecule inhibitors. The cover image demonstrates results of an mRNA expression array analysis of MEK-related gene predictors of response to MEK inhibitors. Genes in the upper panel predict sensitivity to MEK inhibitors, whereas those in the lower panel predict resistance. In the tree, yellow end-nodes denote basal-type cell lines and pink end-nodes denote luminal cell lines. These data, in conjunction with the additional finding of interconnectivity between the MEK and PI3 kinase signal transduction pathways, have implications for future clinical trials of MEK inhibitors and also suggest rationally designed combination therapies. For details, see the article by Mirzoeva and colleagues on page 565 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
AACR Centennial Series
Reviews
Meeting Reports
Priority Reports
Cell, Tumor, and Stem Cell Biology
De novo Induction of Genetically Engineered Brain Tumors in Mice Using Plasmid DNA
Tenascin-C Is a Novel RBPJκ-Induced Target Gene for Notch Signaling in Gliomas
Endocrinology
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Epigallocatechin-3-Gallate, a Histone Acetyltransferase Inhibitor, Inhibits EBV-Induced B Lymphocyte Transformation via Suppression of RelA Acetylation
Immunology
Quantitative DNA Methylation Analysis of FOXP3 as a New Method for Counting Regulatory T Cells in Peripheral Blood and Solid Tissue
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Molecular Biology, Pathobiology, and Genetics
Helicobacter pylori Cytotoxin-Associated Gene A Activates the Signal Transducer and Activator of Transcription 3 Pathway In vitro and In vivo
Chromosomal Signatures of a Subset of High-Grade Premalignant Cervical Lesions Closely Resemble Invasive Carcinomas
High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors
Prevention
Systems Biology and Emerging Technologies
Letters to the Editor
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.